BeAT-HF

Patient Information

The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).

Study Contact: cardiovascularresearch@conehealth.com

Study Number

BeAT-HF

Principal Investigator(s)

James Allred, MD

Dalton McLean, MD

Clinical Trial Categories

• Congestive Heart Failure/CHF